There is a prescription depression treatment that has been sold for years, carries Food and Drug Administration approval, is only given in monitored medical offices, and still draws a blank from most of the Midwest adults we polled.
Its name is Spravato. Of the 443 people who took our survey, nearly three in four, 73 percent, said the word rang no bell at all. A further 21 percent had seen or heard it somewhere yet could not say what it was for. Six percent said they could actually describe it.
This article is the plain explanation those numbers say is missing. It is background, not medical advice; whether the medicine fits you is a judgment for a clinician who has your chart.
Start with the words
Spravato is a brand name. The medication inside it is esketamine, a close chemical relative of ketamine. Ketamine itself has been used in medicine since the 1960s, mostly as an anesthetic, and that history is part of why the newer psychiatric use surprises people.
Esketamine comes as a spray you take through the nose. The FDA label covers treatment-resistant depression, meaning major depression that has hung on after fair trials of two or more antidepressants. A second, narrower label applies when an adult with major depression is also in a suicidal crisis. Either way, patients keep taking an oral antidepressant; the spray is an addition, not a replacement.
You do not pick up a Spravato prescription at a pharmacy counter and use it at home. The drug ships only to certified sites under a restricted program. You hold the device and spray it yourself while a clinician watches, you stay put for a stretch of observation, and a friend or relative takes the wheel afterward.
The distinction that gets blurred constantly
- Spravato, the branded esketamine, holds FDA approval for the uses described above, and every dose happens in a certified room with required observation.
- Generic ketamine given by IV drip for low mood is off label. The drug is approved, just not for this purpose, and practice varies widely from one clinic to the next.
- Ketamine prescribed for home use, often through an online service, sits one step further out. It has grown fast, it has drawn regulators' attention, and it skips the monitored-setting rules that bind the approved spray.
People lump the three together. They differ in approval, supervision, price, and evidence.
Why so few people know it exists
Our respondents' answers point to a few forces that compound into that 73 percent blank.
The first is structural. A medication given only in certified locations is not on every pharmacy shelf, so nobody stumbles across it. Awareness tends to follow the route a treatment takes, and this route is narrow.
The second is that people expect a clinician to do the introducing. Picture wanting this kind of care tomorrow: where do you go? Our respondents' first pick was their primary care doctor, at 56 percent, with a psychiatrist or other mental health professional next at 23 percent. Independent online searching drew only 12 percent, and 5 percent confessed they would be stuck with no starting point.
The third is language. Our open question asked for the literal words people would enter into a search box when hunting for help. They wrote what they felt and what they needed: depression help, treatment for PTSD, a nearby therapist, some alternative to their depression medicine. Nobody typed a brand name, so brand-shaped information never reaches them.
Unfamiliar, but not unwelcome
Low awareness does not mean resistance. We described ketamine-based care for depression or post-traumatic stress and let people tell us their honest first impression. Cautious but open was where 34 percent landed, the single largest group. Skeptics made up 21 percent, the hopeful or curious 18 percent, those who had never heard of the idea another 18 percent, and outright negative reactions 9 percent.
What seems to convert caution is official standing. Approval by the FDA would settle things or count heavily for 59 percent of the sample, and 27 percent ranked it in their top two provider criteria. That is one practical reason the approved versus off-label line matters to patients, not only to regulators.
Questions worth asking before anything else
If this is your first encounter with any of it, cover these in a first conversation.
- Which treatment are we actually discussing, the approved spray or something else, and what is its standing for my diagnosis?
- Have my earlier antidepressant trials been long enough, at high enough doses, to count?
- What in my history might rule this out or raise the risk, such as blood pressure, past substance use, or other prescriptions?
- How often would I come in, how long does a visit run, and who gets me home?
- What does my plan require on paper, and what would I owe?
- What else is worth trying first or instead, from other medication strategies to talk therapy?
That money question is not a footnote. Coverage landed in the top two provider criteria for 85 percent of the people we surveyed, and 65 percent told us insurance would be the whole ballgame or close to it. For a sense of how a certified clinic describes the visits and the paperwork, you can read Brain Recovery Centers' overview of Spravato treatment alongside your plan documents.
What nobody should promise you
No psychiatric treatment helps everyone, and an honest account of this one makes no promises. Esketamine can cause dissociation and a jump in blood pressure during a session, which is why the observation period exists. It is not a first step or a fit for every patient, and the decision belongs with a clinician who can weigh your whole history.
Three in four adults are choosing depression care without knowing this option exists. Knowing about it just makes the choice real.
If your depression has ever turned into thoughts of suicide, please do not sit on it. Anyone in the U.S. can text or phone 988 and be connected to the Suicide and Crisis Lifeline at no charge, any hour, privately. It is there for bad nights, not only emergencies.
Methodology
This publisher paid for the research and commissioned it. Pollfish recruited respondents from its consumer panel; 443 adults between 18 and 64, living in ten Midwest states, completed it before the June 23, 2026 close, each after agreeing to a consent screen. On questions where more than one answer could be checked, the shares add up to over 100. These results come from Pollfish's final, validated responses.